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Table 1. Risk factor analysis of transplant outcomes in 72
patients with T-ALL treated with haplo-identical/mismatched
HSCT
Risk factor LFS Relapse NRM
HLA non-identical locus
1-2 n 5 31 52% 24% 17%
3 n 5 41 39% 21% 35%
p 0.15 0.77 0.068
Gender
Male n 5 55 51% 21% 21%
Female n 5 17 16% 27% 53%
p 0.040 0.61 0.08
Diagnostic WBC
Less than 100 n 5 57 48% 23% 23%
100 or more n 5 15 27% 22% 46%
p 0.27 0.99 0.22
CNS involvement
Yes n 5 12 58% 33% 8%
No n 5 60 37% 21% 33%
p 0.44 0.29 0.09
Tumor mass
Yes n 5 38 37% 33% 32%
No n 5 34 52% 10% 24%
p 0.14 0.02 0.64
Time from chemo to CR1
#30d n 5 40 48% 18% 28%
>30d n 5 32 38% 29% 26%
p 0.12 0.19 0.70
Disease status before HSCT
CR1 n 5 56 58% 18% 16%
Non-CR1 n 5 16 12% 37% 50%
p 0.001 0.08 0.04
Disease duration before HSCT
#7 months n 5 38 50% 23% 23%
>7 monts n 5 34 37% 22% 33%
p 0.42 0.96 0.39
Age
< 35 years n 5 59 42% 26% 24%
$35 years n 5 13 47% 8% 43%
p 0.87 0.17 0.12
Median MNCs, x108/kg
#7.5 n 5 36 40% 21% 34%
>7.5 n 5 36 50% 24% 22%
p 0.61 0.58 0.15
Poster Session II S343irradiation (PPTBI) and evaluate these variables as predictors of
post-SCT survival.
Design & Methods: The study employed a retrospective, descrip-
tive design with convenience sampling of patients treated with
PPTBI at the University of Rochester Medical Center 2001-2010;
De-identified data were extracted from the medical records on IRB
approved protocol. All statistical analyses were performed utilizing
SPSS 19.0.
Results: In the final sample size of 103 patients, mean recipient age
was 56.6 (SD9.9; range 20-70). The sample was 34% female and 66%
male. Disease type included ALL (1.9%), AML (33%), CLL
(20.4%), CML (4.9%), HL (4.9%), MDS (8.7%), MM (1.9%),
MPN (6.8%), NHL (16.5%), and PCD (1%). Disease status in-
cluded: 1st response (30.1%), 2nd response (38.8%), refractory
(16.5%), untreated (4.9%), and other (9.7%). Related (43.7%) and
unrelated (56.3%) donors were utilized. HCT-CI scores were cate-
gorized into low (10.7%), intermediate (31.1%), and high (58.3%)
risk. Median survival was 298 days (SD825.4; range10-2881);
38.8% were alive at study endpoint. Bivariate analyses (alpha 5
.05) revealed a significant association between survival and age, dis-
ease type, disease status, and HCT-CI category (all p\.001), but not
donor relatedness. Survival was regressed on the explanatory vari-
ables with stepwise addition of HCT-CI which remained the only
significant predictor of survival in this sample (c2 5 11.35, df 2,
p 5 .003). Subjects in low (HR .31,95% CI:.101,.961, p 5 .042)
and intermediate (HR .41, 95%CI:.214,.775, p 5 .006) groups by
HCT-CI had significantly better survival compared to those in the
high risk group.
Conclusion:Our findings contribute to the validity and reliability of
HCT-CI as a predictor of survival after reduced intensity SCT in all
types of hematologic malignancies. We conclude that the HCT-CI
assessment should routinely be performed to facilitate risk estima-
tion and decision-making with patients who are considering SCT
and further prospective studies are needed to confirm these
findings.
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A NOVEL PROTOCOL FOR HAPLOIDENTICAL HSCT WITHOUT IN VITRO
T CELL DEPLETION IN THE TREATMENT OF SEVERE ACQUIRED APLASTIC
ANEMIA
Xu, L.-P., Liu, K.-Y., Liu, D.-H., Han, W., Chen, H., Chen, Y.-H.,
Zhang, X.-H., Wang, Y., Wang, F.-R., Wang, J.-Z., Huang, X.-J. Pe-
king University People’s Hospital, Peking Univeristy Institute of Hematol-
ogy, Beijing, China
Mismatched related donor HSCT for severe aplastic anemia
(SAA) presents challenges, mainly associated with graft failure and
GVHD. Non-engraftment and graft rejection after allo-HSCT for
SAA has been strongly associated with higher degrees of histoincom-
patibility and allosensitization to histocompatibility antigens due to
previous blood product transfusions. Earlier reports have suggested
that the greater the HLA disparity, the poorer the overall survival
(OS), less than 20% survival for two or more loci-mismatched recip-
ients. Recently, progress has been made in haploidentical HSCT,
which is now used to perform haploidentical non-T-cell-depleted
HSCT for patients with hematological malignancies, it is not known
whether the similar procedure could be used for patients with SAA.
We report the results of 19 consecutive SAA/VSAA patients who re-
ceived haploidentical-HSCT. All cases failed to previous therapy and
were heavily transfused prior to transplantation. Among these, 9
cases had 3 loci mismatches, 9 cases had 2 loci mismatches, and 1
case had 1 locus mismatch. All patients were treated with a regimen
which consisted of the following: busulfan (6.4mg/kg i.v. in 8 doses);
cyclophosphamide (200mg/kg, i.v. in 4 doses); and ATG (10mg/kg
i.v.,rabbit, of the Sangstat product or 80mg/kg i.v.,porcine,the Bio-
product, Wuhan, in 4 doses).All recipients received CsA, mycophe-
nolate mofetil, and short-term MTX for GVHD prophylaxis. The
source of stem cell grafts was a combination of G-CSF-primed
BM and G-CSF-mobilized peripheral blood stem cells. All patients
achieved 100%donormyeloid engraftment; themedian time formy-
eloid engraftment was 12 days (ranging from 10-29 days) and 18 days
(ranging from 8-180 days) for platelets, with a cumulative platelet en-
graftment incidence of 84.21 6 10.53%. Two patients (10.5%) suf-
fered late graft rejection. The cumulative incidence was 42.1 6
11.3% for grade II-IV acute GVHD (aGVHD) and 21.1 6 9.4%for grade III-IV aGVHD. The cumulative incidence was 56.2 6
12.4% for chronic GVHD (cGVHD) and 12.56 8.3% for extensive
cGVHD.Of 13 surviving patients with amedian 746 d (90-1970) fol-
low-up, OS was 64.66 12.4%. The independent high risk factors to
OS are grade II-IV aGVHD and mononuclear cells (MNC) infused
\8.84x108/kg. These limited data suggest that HLA-mismatched/
haploidentical HSCT for SAA patients without an HLA-identical
sibling donor may be feasible. Properly controlled trials will be
needed to confirm this conclusion.
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The outcome of T-cell acute lymphoblastic leukemia (T-ALL)
is poorly understood. Allogeneic hematopoietic stem cell
S344 Poster Session IItransplantation (HSCT) remains one of the best options to cure T-
ALL. However, many patients cannot find an HLA-matched do-
nor. Our institute established a new protocol for haplo-identical
HSCT. Busulfan, cyclophosphamide, cytosine arabinoside and
methyl CCNU plus anti-thymocyte globulin was used for condi-
tioning therapy. Seventy-two patients diagnosed with T-ALL un-
derwent transplantation from haplo-identical donor family
members. Risk factor analysis are summarised in Table 1. The in-
cidence rates of grades II to IV acute graft versus host disease
(aGVHD) and of grades III and IV aGVHD were 49%612%
and 19%612%, respectively. The cumulative incidence rate for
chronic GVHD (cGVHD) at two years after HSCT was 41%6
12%. After a median follow-up of 12 months, fifteen patients had
relapsed, fourteen died from relapse, and forty-one patients were
still alive without disease recurrence. The probability of leuke-
mia-free survival (LFS) was 44.2%67.4% at three years.Patients
transplanted during their first complete remission (CR1 had a lower
relapse rate (18.8% vs. 37.5%, p 5 0.049, with a RR 5 0.247, p 5
0.007), a lower non-relapse mortality (NRM) rate (16.6% vs.
50.0%, p 5 0.046, with a RR 5 0.279, p 5 0.024) and better
LFS (54.8% vs 12.5%, p 5 0.001, with a RR 5 0.315, p 5
0.004) compared with patients transplanted beyond CR1. This
study confirmed that haplo-identical/mismatched HSCT could be
an alternative treatment choice for T-ALL.377
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Allogeneic stem cell transplantation (allo-SCT) is considered
the best post-remission therapy for patients with Ph+ALL. How-
ever, the application of this procedure is limited by the availabil-
ity of suitable HLA-compatible donors. Umbilical cord blood
transplantation (UCBT) from unrelated donors has emerged as
an alternative approach for patients lacking an HLA-matched
donor. This study compares the clinical outcome of 36 adults
with Ph+ALL who received either UCBT from unrelated donors
(n 5 25) or bone marrow or peripheral blood stem cell trans-
plantation (BMT/PSCT) from HLA-matched sibling donors
(n 5 11) at a single institution. From June 1999 to August
2010, all consecutive patients with Ph+ALL, except one who re-
ceived total body irradiation, received busulfan, thiotepa, and cy-
clophosphamide or fludarabine as myeloablative conditioning
regimen. Antithymocyte globulin was added in UCBT patients.
All patients received cyclosporine as graft-versus-host disease
prophylaxis, combined prednisone or mycophenolate mofetil in
UCBT or methotrexate in matched-sibling allo-SCT. Median
age was 33 years (range, 16-54) and 21 (58%) were males. At
time of transplantation, 28 (78%), 3 (8%) and 5 (14%) were in
first complete remission (CR), second or further CR and more
advanced phase of the disease, respectively. Patient and disease
characteristics were similar in both groups. Except for one pa-
tient undergoing UCBT that experienced primary graft failure,
all remaining patients engrafted. Myeloid engraftment was faster
in BMT/PSCT than UCBT (median 12 days vs 20 days; p\
0.01). With a median follow-up of surviving patients of 41
months (range 15-114), the 4-year CI of NRM for UCBT and
BMT/PSCT recipients was 36% and 9%, respectively (p 5
0.1), and the CI of relapse 22% and 64%, respectively (p 5
0.15). Disease-free survival at 4 years was 42% in UCBT and
27% in matched-sibling allo-SCT recipients; (p 5 0.6). Our
data suggest that for patients with Ph+ALL, UCBT from unre-
lated donors is a reasonable approach with efficacy similar to
that of BMT/PSCT from HLA-identical sibling.378
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Weprospectively assess, in pts over 55years, eligible for anmatched
sibling Allo-SCT, the impact of a RIC with Fludarabine (30 mg/m2/
day (D-5 toD-1)), IVBusulfan (0.8mg/kg x 4/day (D-4 toD-3)) and r-
ATG (2.5 mg/kg/day (D-2 to D-1). Eventually, from 03/07 to 06/10,
82 pts have been included, of which 79 have been transplanted. Me-
dian follow-up is 24 months (10-50). All grafts were PBSC from
aHLA identical sibling. CSA (2mg/kg) was started on day -2.Median
age is 60 (55-70). Karnofsky score was 90 (60-90). Diagnoses: AML5
32;MDS5 13; ALL5 6; NHL5 10;MM5 13; Others5 5); 54 pts
were in CR (CR15 31; CR25 15; CR.25 8), 22 in PR or SD and 3
inPDafter amedianof 2 (1-7) lines of chemotherapy.All pts engrafted
and 46 presented with aGVHD (G1 n5 32; G2: n5 7; G3-4: n5 6)
for a 17% (10-23) cumulative incidence of G$ 2 aGVHD. A total of
47 pts had cGVHD (Limited: N5 28; extensive: N5 19) at a median
of 4.5 months (3-21) for a one year overall and extensive cumulative
incidence of 57% (46-68) and 34% (25-45) respectively. 12 pts died
from NRM. The 6 month and overall cumulative incidences of
NRM were 5% (0-10) and 16% (9-23) respectively. Karnofsky score
was not predictive ofNRM. 25 pts relapsed at a median of 4.2months
(0.8-12) for a cumulative incidence of 32% (23-42). Relapse incidence
differed according to disease pre-transplant status (9 of 46 CR1/CR2
vs. 16 of 33 beyond CR2 pts; p 5 0.008). Three year overall and dis-
ease-free survival probabilities were 79% (67-87) and 59% (45-71) re-
spectively. Considering the CR1 AML population (N5 21), median
age was 61 years (56-70) and probabilities of NRM, relapse, OS and
LFS were 14% (IC95 5 0-27), 14% (IC95 5 2-26), 72% (IC95 5
47-86) and 67 % (IC955 43-83) respectively. Economic data cover-
ing transplant and first 18 month post-transplant periods have been
prospectively collected and are under analysis. HRQL (Health Re-
lated Quality of Life) was assessed over a 1-year period with the
EORTC QLQ-C30 questionnaire (Days -7, +80, +180, +360). The
lowest functioning scores and highest symptom scores were experi-
enced 80 days after transplantation. Thereafter the level of function-
ing and level of symptoms returned to baseline levels, which is
reassuring in this population. Taking account patient characteristics,
results confirm that Allo-SCT after RIC is a valid option in this pop-
ulation, that RI. Further refining of this association, by cautious tun-
ing of the IV Busulfan dose, is under process in our program.379
FLUDARABINE AND CYCLOPHOSPHAMIDE PROVIDE A NON-MYELOA-
BLATIVE ALTERNATIVE CONDITIONING REGIMEN WITH LOW TRANS-
PLANT-RELATED MORTALITY AND CONTROL OF HIGH RISK DISEASE
Paplham, P., Hahn, T., Brown, K., Syta, M., Dubel, K., Lipka, P.,
McCarthy, P. Roswell Park Cancer Institute, Buffalo, NY
Myeloablative allogeneic hematopoietic cell transplant (MAT)
regimens are associated with significant transplant-related mortality
(TRM). Non-myeloablative (NMAT) regimens have a curative po-
tential for patients who would not be considered MAT candidates
due to factors such as older age, co-morbidities, prior failed MAT
or poor Karnofsky Performance Score (KPS). We performed a pro-
spective phase II clinical trial of a NMAT regimen with the objec-
tives to determine TRM, progression-free (PFS) and overall
survival (OS). Forty patients were enrolled April 2002 - December
2008 at a single center and received cyclophosphamide 50 mg/kg/d
